Skip to content

Your cart is empty

Continue shopping

Tunica Albuginea: The Key Structure in Traction Therapy

The tunica albuginea is the bi-layered collagen sheath that determines penile rigidity and serves as the primary target tissue for penile traction therapy.


Listen to this article
Audio
Video Watch: Tunica Albuginea Anatomy & Traction Therapy Explained
Tunica Albuginea: The Key Structure in Traction Therapy
🧬 Anatomy & Mechanism · Danamedic

🧬 Key Facts

  • Structure — The tunica albuginea is a tough fibrous sheath composed of Type I and Type III collagen fibers interwoven with elastin
  • Architecture — Two distinct layers: an inner circular layer and an outer longitudinal layer (Hsu et al., 1994)
  • Thickness — Tunica albuginea thickness ranges from 0.8 mm to 2 mm depending on anatomical location
  • Function — The tunica albuginea contains pressurized blood within the corpora cavernosa to produce penile rigidity during erection
  • Traction Target — Penile traction therapy applies calibrated mechanical force to the outer longitudinal fibers, stimulating collagen remodeling

🧬 What Is the Tunica Albuginea?

The tunica albuginea is a dense, fibrous envelope of connective tissue that surrounds each of the two corpora cavernosa within the penile shaft. Described in Gray's Anatomy as one of the strongest fascial structures in the human body, the tunica albuginea provides the structural framework that makes penile erection mechanically possible.

The tunica albuginea is composed primarily of Type I and Type III collagen fibers interwoven with elastin fibers. Type I collagen provides tensile strength. Type III collagen contributes structural flexibility. Elastin fibers allow the tunica albuginea to stretch during erection and return to resting length afterward. Fibroblasts within the tunica albuginea continuously produce and maintain the collagen-elastin matrix.

Hsu and colleagues, publishing in the Journal of Urology in 1994 (PMID: 8158761), described the bi-layered architecture of the tunica albuginea. The inner circular layer consists of collagen fibers oriented circumferentially around each corpus cavernosum. The outer longitudinal layer consists of collagen fibers running along the length of the penile shaft.

The inner circular fibers resist lateral expansion and maintain girth. The outer longitudinal fibers resist elongation along the penile axis. Tunica albuginea thickness varies by anatomical location, ranging from 0.8 mm to 2 mm.

Brock and colleagues, publishing in Urology in 1997, established that the tunica albuginea exhibits viscoelastic and anisotropic behavior — responding differently to force depending on the direction of load. A separate chamber — the corpus spongiosum — surrounds the urethra and has a thinner tunical covering.

📸 Image will appear here once uploaded

Cross-section diagram of the tunica albuginea showing its bi-layered structure surrounding the corpora cavernosa

📸 Image will appear here once uploaded

Diagram showing the inner circular and outer longitudinal collagen fiber layers of the tunica albuginea
Layer Fiber Orientation Primary Function Role in Traction Therapy
Inner Circular Layer Circumferential — around each corpus cavernosum Resists lateral expansion, maintains girth during erection Secondary — some response to girth traction
Outer Longitudinal Layer Longitudinal — along the penile shaft axis Resists elongation, limits penile length Primary target — sustained traction stimulates collagen remodeling and permanent elongation

💡 Why the Tunica Albuginea Matters for Erections

The tunica albuginea serves as the pressure-containment vessel that makes penile erection possible. During sexual arousal, arterial blood flows into the sinusoidal spaces of the corpora cavernosa. The tunica albuginea must withstand intracavernosal pressures exceeding 100 mmHg to maintain full rigidity.

The veno-occlusive mechanism depends entirely on tunica albuginea function. As the corpora cavernosa fill with blood, expanding sinusoidal tissue compresses subtunical venules against the inner surface of the tunica albuginea. The tunica albuginea traps blood inside the corpora cavernosa by preventing venous outflow. Damage to the tunica albuginea compromises the veno-occlusive mechanism and can result in erectile dysfunction.

Goldstein, writing in the Textbook of Female and Male Sexual Medicine (2007), documented that tunica albuginea composition changes with age. Collagen-to-elastin ratios shift over time, with elastin content decreasing and collagen cross-linking increasing. The tunica albuginea gradually loses compliance, contributing to the progressive decline in erectile quality experienced after age 50.

When the tunica albuginea sustains localized damage, scar tissue — known as plaque — can form within the collagen matrix. Plaque formation within the tunica albuginea is the defining pathology of Peyronie's disease. Peyronie's disease affects an estimated 3–9% of adult men.

🎯 How Penile Traction Therapy Targets the Tunica

Penile traction therapy applies sustained, calibrated mechanical force along the longitudinal axis of the penis. The force directly loads the outer longitudinal fibers of the tunica albuginea — the primary tissue layer that resists elongation. Sustained traction overcomes the resting tension of the outer longitudinal fibers, activating a biological cascade that results in permanent tissue elongation.

📸 Image will appear here once uploaded

Illustration showing how penile traction therapy applies force to the outer longitudinal fibers of the tunica albuginea

The cellular response to sustained mechanical loading is called mechanotransduction — the biological process by which cells convert mechanical force into biochemical signals. Fibroblasts within the tunica albuginea detect mechanical strain through integrin receptors on the cell surface. Fibroblast activation triggers increased production of Type I and Type III collagen, along with elastin and extracellular matrix proteins.

Chung and Brock, publishing in the Journal of Sexual Medicine in 2013 (PMID: 23421851), demonstrated through histological analysis that sustained mechanical strain produces "reorganization and remodelling of collagen fibres into uniform densely packed fibrils parallel to the axis of mechanical strain." New collagen remodeling under traction creates additional tissue through cellular proliferation — not simple stretching of existing fibers.

The underlying medical principle is tissue expansion — the same biological mechanism used in reconstructive surgery, orthodontics, and limb-lengthening procedures. Tissue expansion operates through a Wolff's Law analog in connective tissue: sustained mechanical loading stimulates adaptive growth in the direction of applied force.

📸 Image will appear here once uploaded

Infographic showing the collagen remodeling process in the tunica albuginea under traction therapy

🔬 Key Mechanism

Sustained traction activates fibroblasts within the tunica albuginea, stimulating new collagen deposition and tissue elongation. The biological response is permanent structural growth confirmed by histological analysis — not temporary stretching (Chung & Brock, 2013).

📊 Clinical Evidence — Tunica Response to Traction

Gontero and colleagues, publishing in the Journal of Sexual Medicine in 2009 (PMID: 19138361), measured penile traction outcomes in 15 patients with Peyronie's disease. Gontero reported a mean length gain of 1.3 cm (0.5 inches) after six months of daily penile traction device use at 4–6 hours per day. Traction-induced changes in the tunica albuginea were maintained at follow-up, with no regression of gains after treatment cessation.

Levine and colleagues, publishing in the Journal of Sexual Medicine in 2008 (PMID: 18355100), evaluated penile traction therapy for Peyronie's disease treatment. The Levine study documented measurable improvements in both penile length and curvature correction through sustained mechanical loading of the scarred tunica albuginea.

Nikoobakht and colleagues, publishing in the Journal of Sexual Medicine in 2011 (PMID: 21054389), reported gains of 1.7 cm (0.7 inches) in both flaccid and stretched penile length in 23 participants using a penile extender device for three months.

📊 Almsaoud, Safar, and Alshahrani (2023) — Systematic Review & Meta-Analysis
The 2023 systematic review and meta-analysis, published in Translational Andrology and Urology (PMID: 38106680), pooled data from twelve clinical studies involving over 1,000 patients. The Almsaoud meta-analysis calculated a weighted mean length gain of 1.9 cm (0.75 inches) with an 82% adherence rate. Curvature improvement averaged 27% in patients with Peyronie's disease.
→ PubMed PMID: 38106680
🇺🇸 Avant, Ziegelmann et al. (2019) — Systematic Review
Avant, Ziegelmann, and colleagues, publishing in Sexual Medicine Reviews in 2019 (PMID: 29631979), concluded that penile traction therapy produces consistent, measurable changes through fibroblast-mediated collagen remodeling within the tunica albuginea. No serious adverse events were reported across the reviewed studies.
→ PubMed PMID: 29631979
🇺🇸 Ziegelmann et al. (2019) — Post-Prostatectomy Study
Ziegelmann and colleagues, publishing in the Journal of Urology in 2019 (PMID: 30916626), demonstrated that early application of traction to the tunica albuginea following prostatectomy helps preserve penile length by preventing fibrotic contraction during post-surgical healing.
→ PubMed PMID: 30916626
🇺🇸 Joseph et al. (2020) — Randomized Controlled Trial
Joseph and colleagues, publishing in the Journal of Sexual Medicine in 2020 (PMID: 33223425), studied 110 participants in a randomized controlled trial of penile traction therapy. The Joseph trial reported that 94% of participants achieved measurable increased penile length through sustained traction force applied to the outer longitudinal fibers of the tunica albuginea.
→ PubMed PMID: 33223425
🇺🇸 Toussi et al. (2021) — Randomized Controlled Trial
Toussi and colleagues, publishing in the Journal of Urology in 2021 (PMID: 34060339), conducted a separate trial of 82 men and documented gains of 1.6 cm versus 0.3 cm in the control group (p<0.01). Toussi reported that 87% of participants expressed willingness to repeat penile traction therapy and 93% would recommend traction to others.
→ PubMed PMID: 34060339

The combined clinical evidence from the Joseph, Toussi, Gontero, and Nikoobakht trials confirms that penile traction devices — including the FDA-registered SizeGenetics device — produce measurable penile lengthening results of 1.3–2.3 cm over 3–6 months of daily use through sustained collagen remodeling within the tunica albuginea.

0.8–2 mm
Tunica Thickness
2 Layers
Bi-Layered Architecture
1.9 cm
Mean Gain (Meta-Analysis)
15+
Peer-Reviewed Studies

🩺 Tunica Albuginea and Peyronie's Disease

Peyronie's disease is a condition in which fibrous plaque forms within the tunica albuginea, causing penile curvature, shortening, pain, and erectile difficulty. The plaque consists of disorganized collagen deposits — dense scar tissue that replaces the normal bi-layered architecture with rigid, non-elastic fibrous tissue.

During erection, healthy segments of the tunica albuginea expand normally while the plaque-affected segment remains rigid. The asymmetric expansion creates penile curvature toward the plaque side. Penile traction therapy for Peyronie's disease applies sustained mechanical force directly to the plaque within the tunica albuginea.

Traction therapy remodels Peyronie's plaque by gradually stretching disorganized scar tissue and stimulating fibroblast activity at the plaque margins. Over 3–6 months of daily traction at 4–6 hours per day, rigid plaque undergoes gradual softening and collagen reorganization. The Almsaoud meta-analysis (2023, PMID: 38106680) confirmed an average curvature improvement of 27% with concurrent length gains offsetting disease-related shortening.

🏥 Peyronie's Disease — Traction Therapy Evidence

The 2023 Almsaoud meta-analysis pooled data from twelve studies involving over 1,000 patients and confirmed a mean 27% curvature improvement through sustained traction applied directly to Peyronie's plaque within the tunica albuginea. The European Society for Sexual Medicine has endorsed penile traction therapy as a recommended non-surgical treatment for stable-phase Peyronie's disease.

⚙️ How SizeGenetics Applies Calibrated Traction to the Tunica

The SizeGenetics penile traction device is an FDA-registered Class II medical device manufactured by Danamedic ApS in Denmark. Danamedic ApS, founded in 1988, invented the penile traction device in 1994. SizeGenetics applies calibrated, sustained mechanical force along the longitudinal axis of the penis, directly loading the outer longitudinal fibers of the tunica albuginea.

The 58-way Multi-Axis Comfort Technology distributes traction force evenly across the penile shaft, preventing point-loading that could damage the tunica albuginea. The SizeGenetics tension range spans 900–2,800 grams (8.8–27.5 Newtons). The maximum traction force across all Danamedic brands — including MaleEdge, Jes-Extender, and SizeGenetics — reaches 3,200 grams (31.4 Newtons).

Dr. Jørn Ege Siana, the plastic surgeon and co-inventor of the penile traction device, designed the original device based on tissue expansion principles from reconstructive plastic surgery. The clinical protocol recommends 4–6 hours of daily wear over a treatment duration of 3–6 months. Clinical studies across 15+ peer-reviewed publications involving over 1,000 patients have reported no serious adverse events from penile traction therapy.

👨‍⚕️
Co-Inventor of the SizeGenetics Device

Dr. Jørn Ege Siana, M.D.

Dr. Jørn Ege Siana, plastic surgeon and co-inventor of the penile traction device category, designed the original SizeGenetics device in 1994 drawing on tissue expansion principles from reconstructive plastic surgery. His clinical experience with mechanotransduction-driven tissue growth informed the therapeutic tension window and device architecture that applies calibrated force directly to the outer longitudinal fibers of the tunica albuginea.

  • Board-certified plastic surgeon, Copenhagen, Denmark
  • Co-inventor of the penile traction device category (patent filed February 1995)
  • Medical advisor to Danamedic ApS — Danish medical device manufacturer founded in 1988
🏥
FDA Registered
Class II Medical Device
🇪🇺
CE Marked
European Conformity
🇩🇰
Danamedic ApS
Danish Manufacturer Est. 1988
🔬
15+ Studies
Peer-Reviewed Evidence
6-Month Guarantee
Full Money-Back Promise

Frequently Asked Questions

What is the tunica albuginea made of?

The tunica albuginea is composed primarily of Type I and Type III collagen fibers interwoven with elastin fibers. Type I collagen provides tensile strength, Type III collagen contributes flexibility, and elastin allows the tunica albuginea to stretch during erection. Hsu and colleagues (1994, PMID: 8158761) described the tunica albuginea as having an inner circular layer and an outer longitudinal layer of collagen fibers.

Can the tunica albuginea be permanently stretched?

The tunica albuginea can be permanently elongated through sustained mechanical loading that activates fibroblast-mediated collagen remodeling. Penile traction therapy applies calibrated force to the outer longitudinal fibers, stimulating new collagen deposition through mechanotransduction. The 2023 meta-analysis by Almsaoud and colleagues (PMID: 38106680) confirmed a weighted mean length gain of 1.9 cm across twelve pooled clinical studies.

Does Peyronie's disease affect the tunica albuginea?

Peyronie's disease is defined by fibrous plaque formation within the tunica albuginea. The plaque consists of disorganized, dense scar tissue that replaces normal bi-layered collagen architecture. Peyronie's plaque prevents normal expansion during erection, causing curvature, shortening, and erectile difficulty. Peyronie's disease affects an estimated 3–9% of adult men.

How long does tunica remodeling take with traction?

Tunica albuginea remodeling under penile traction therapy requires 3–6 months of consistent daily use at 4–6 hours per day. Fibroblast activation and new collagen deposition begin within the first weeks. Measurable changes in penile length typically become apparent after 8–12 weeks. Optimal results are documented at six months of daily traction therapy.

Is traction therapy safe for the tunica albuginea?

Across 15+ peer-reviewed studies involving over 1,000 patients, no serious adverse events have been reported from penile traction therapy. The adverse event rate ranges from 11.2–14.4%, with all reported events classified as mild and temporary — including minor erythema and transient discomfort. The SizeGenetics device applies force within the tunica albuginea's elastic limit.

📚 Continue Learning About Penile Traction Therapy

Understanding the tunica albuginea is the foundation of understanding penile traction therapy. The following pages explore the clinical mechanisms, evidence, and applications of mechanotransduction-driven tissue growth in practice.

⚕️ Medical Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before beginning any medical device therapy. Clinical study results represent group averages; individual results may vary. SizeGenetics is a registered Class II medical device manufactured by Danamedic ApS.